Butyrate Modification Promotes Intestinal Absorption and Hepatic Cancer Cells Targeting of Ferroptosis Inducer Loaded Nanoparticle for Enhanced Hepatocellular Carcinoma Therapy
Authors:
Abstract
Sorafenib is an oral‐administered first‐line drug for hepatocellular carcinoma (HCC) treatment. However, the therapeutic efficacy of sorafenib is relatively low. Here, an oral delivery platform that increases sorafenib uptake by HCC and induces potent ferroptosis is designed. This platform is butyrate‐modified nanoparticles separately encapsulated with sorafenib and salinomycin. The multifunctional ligand butyrate interacts with monocarboxylate transporter 1 (MCT‐1) to facilitate transcytosis. Specifically, MCT‐1 is differentially expressed on the apical and basolateral sides of the intestine, highly expressed on the surface of HCC cells but lowly expressed on normal hepatocytes. After oral administration, this platform is revealed to boost transepithelial transport effectively and continuously in the intestine, drug accumulation in the liver, and HCC cell uptake. Following drug release in cancer cells, sorafenib depletes glutathione peroxidase 4 and glutathione, consequently initiating ferroptosis. Meanwhile, salinomycin enhances intracellular iron and lipid peroxidation, thereby accelerating ferroptosis. In vivo experiments performed on the orthotopic HCC model demonstrate that this combination strategy induces pronounced ferroptosis damage and ignites a robust systemic immune response, leading to the effective elimination of tumors and establishment of systemic immune memory. This work provides a proof‐of‐concept demonstration that an oral delivery strategy for ferroptosis inducers may be beneficial for HCC treatment.Keywords
This publication has 32 references indexed in Scilit:
- ER stress and the unfolded protein response in neurodegenerationNature Reviews Neurology, 2017
- An iron hand over cancer stem cellsAutophagy, 2017
- Salinomycin kills cancer stem cells by sequestering iron in lysosomesNature Chemistry, 2017
- Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III TrialClinical Genitourinary Cancer, 2017
- Switching Apoptosis to Ferroptosis: Metal–Organic Network for High-Efficiency Anticancer TherapyNano Letters, 2016
- Nanomedicine in management of hepatocellular carcinoma: Challenges and opportunitiesInternational Journal of Cancer, 2016
- Ferroptosis: Death by Lipid PeroxidationTrends in Cell Biology, 2016
- Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosisJournal of Controlled Release, 2016
- Surveillance, Diagnosis, Treatment, and Outcome of Liver Cancer in JapanLiver Cancer, 2015
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984